Menu
NASP

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and latest CE information More Information

Featured Activity

This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Rheumatoid Arthritis

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education (CSPE) 

 
 View more NASP/CSPE Activities

Activity Description

Rheumatoid Arthritis (RA) is an autoimmune disease that affects 1-2% of people worldwide. The diagnosis of RA increases with age and is more commonly seen in women. RA has been shown to decrease life expectancy and is a major factor leading to adult disability. This educational activity will review the pathophysiology, clinical presentation, and diagnosis of RA. The current ACR guidelines for treatment will be reviewed along with the current therapies. Methods used to measure and monitor the effectiveness of treatment, along with patient education, will also be discussed.

Learning Objectives

The target audience for this activity includes pharmacists. Upon completion of this activity, participants will be able to:

  • Identify the major chemicals and cells involved in the pathophysiology of Rheumatoid Arthritis (RA)
  • Describe the clinical presentation and diagnostic criteria
  • Discuss the difference between non-disease modifying drugs and disease modifying anti-rheumatic drugs (DMARDs)
  • Explain 2015 ACR recommendations for the treatment of RA
  • Outline typical use, adverse effects, contraindications and monitoring parameters for non-biologic DMARDs, biologic DMARDs and Janus kinase (JAK) inhibitors
  • Identify methods used to measure efficacy and list the parameters typically evaluated
  • Recall patient education considerations

Faculty

Aimee Chevalier, Pharm.D.
Clinical Pharmacist, Rheumatology Clinic
Clinical Assistant Professor, Department of Pharmacy Practice
University of Illinois at Chicago
Chicago, IL

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation. Aimee Chevalier has no relevant commercial or financial relationships to disclose.

Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include unlabeled indications. Use of drugs and devices outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.

CE Accreditation

Release Date: 03-03-2017
Expiration Date: 03-03-2019

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and the National Association of Specialty Pharmacy (NASP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-17-096-H01-P has been assigned to this knowledge-based, home-study activity. This CE activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers, and is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Funding

No external support has been received for this activity.

 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.